Efficacy and Safety of Rilzabrutinib in Pemphigus: PEGASUS Phase 3 Randomized Study

Pemphigus is a rare, but life-threatening autoimmune disease requiring long-term treatment that minimizes corticosteroid (CS) exposure while providing consistent disease control. The phase 2 pemphigus study of oral, reversible, covalent Bruton tyrosine kinase (BTK) inhibitor rilzabrutinib demonstrated rapid and sustained efficacy with well-tolerated safety.

Source: Journal of Investigative Dermatology - March 15, 2024 Category: Dermatology Authors: Dedee F. Murrell, Fr édéric Caux, Aikaterini Patsatsi, Owen Hagino, Lidia Rudnicka, Snejina Vassileva, Soner Uzun, Jenny Ye, Karl Yen, Puneet Arora, Steven G. Gourlay, Pascal Joly, Victoria P. Werth Tags: Original Article Source Type: research